logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


Buyside analysts don't publish ratings and target prices for the public: Nearly all their notes, analyses and projections are top secret. However, in this interview with The Life Sciences Report, Wasatch Advisors' Jill Wahleithner breaks that tacit rule. Wahleithner, a former big pharma scientist, identifies three unusual biotechs with advanced…
Read more...
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still loom on the political and reimbursement front. Edward Lanphier, founder and CEO…
Read more...
The cosmetic industry is enormous, as everyone already knows. Beauty ideals continue to push the market forward and higher; specifically, the global facial care market, which is forecast  to be worth $40 billion by 2019. To look closer, skin lightening and anti-aging are two of the biggest, most rapidly growing…
Read more...
Valeritas (VLRX)  is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. VLRX is one of four new IPOs scheduled for this week. The full IPO calendar is available at IPOpremium. VLRXscheduled a $75 million…
Read more...
SteadyMed (STDY)  is a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates. VLRX is one of four new IPOs scheduled to IPO this week. The full IPO calendar is available at IPOpremium. The company is based in Rehovot, Israel,and scheduled a $56 million IPO with…
Read more...
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years Markey has seen nearly every type of biotech success and failure, and it has made him take…
Read more...
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not be able to make sense of peer-reviewed scientific literature but want…
Read more...
Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the sector, because no stock lives on an island. The most fabulous fundamentals in the world won't propel a stock against powerful global or industry-wide headwinds. In this…
Read more...
Immuno-oncology—disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it—took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in 2015, bolstered by new drug approvals, new targets and new combination immunotherapies that…
Read more...
Flashback Photobomber Hoodie If you read my recent article Wearable Cameras, you understand that video embedded in clothing is on the horizon and the "point and shoot" camera phone will not be how most photo and video content will be created. Instead, it will be created from someone's hat, or…
Read more...
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based in Canada, where resource stocks have absorbed…
Read more...
The marijuana industry is one with great promise…and relative uncertainty. Navigating the ever-changing regulatory environment is often fraught with difficulties, making it difficult to do the sort of long-term planning that most businesses rely on. However, some companies have found a middle-path, one that leverages the medical benefits of marijuana…
Read more...
Page 1 of 50

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.